Eli Lilly and Company

Other

Elan Pharmaceuticals, Inc.

Athena Neurosciences, Inc.

Qing Shi

James E Audia

Warren Jaye Porter

Bruce Anthony Dressman

Richard Craig Thompson

Stephen Charles Wilkie

Douglas Richard Stack

Michael Robert Wiley

Larry C Blaszczak

Scott Martin Sheehan

Michael Alan Robertson

Shon Roland Pulley

Michael J Martinelli

Thomas Edward Mabry

Jon Kevin Reel

Thomas Charles Britton

Russell Dean Stucky

Brian Morgan Watson

Steven Scott Henry

Stacey L McDaniel

Karin Briner

Richard Duane Johnston

Cynthia L Cwi

Timothy Ivo Richardson

Vincent Mancuso

Christopher William Doecke

Michael James Genin

William Glen Holloway

Chaoyu Xie

John Richard Morphy

Eldon E Vanmeter

John M Schaus

Paul Leslie Ornstein

Matthew Joseph Fisher

David Andrew Coates

Cynthia Darshini Jesudason

Larry W Hertel

John Robert Rizzo

Macklin Brian Arnold

Erik James Hembre, Ii

Jianliang Lu

Chafiq Hamdouchi

Nicholas Paul Camp

Emily Jane Canada

Steven Marc Massey

Brian Michael Mathes

Miles Goodman Siegel

Thomas James Beauchamp

Zhipei Wu

Roger Ryan Rothhaar

John Philip Mayer

Jason Kenneth Myers

Kevin Charles Fortner

Jayana Pankaj Lineswala

Jikesh Arvind Shah

Mark David Rekhter

Christopher Kelly Biggers

Larry Chris Blaszczak

John Mehnert Schaus

The present invention provides a compound of Formula I: wherein Ris methyl, ethyl or cyclopropyl; Ris hydrogen, methyl, or ethyl; Ris methyl or AA; and Ris C2-C4 alkyl, BB; or a pharmaceutically acceptable salt thereof; for use as a PDE1 inhibitor. 

Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors

The present invention provides a compound of Formula I: wherein X is CHCH, CHCHCH, OCH, or CHO; and R is ethyl, n-propyl, cyclopropyl, or cyclobutyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X is CHCH, then R is other than cyclopropyl; for use as a human PDE inhibitor. 

[1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes

The present invention provides a compound of Formula (I), wherein X is H or C1-C3 alkyl optionally substituted with hydroxyl; Y is H, hydroxy, or methyl; R is ethyl, n-propyl, cyclopropyl, or Formula (II); and A is methyl, cyclopropyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X and Y are both H and R is n-propyl, then A is other than methyl; for use as a human PDE1 inhibitor. 

[1,2,4]Triazolo[4,3-A]pyrazin-6(5H)-one derivatives

The present invention provides a compound of Formula I: 

Triazolopyrazinone derivative useful as a human PDE1 inhibitor

The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.

CGRP receptor antagonists

This invention provides compounds of formula I: 

Inhibitors of diacylglycerol acyltransferase

The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (1); X is selected from CH, CF and N; R5 is selected from H, C-Calkyl, C-Cfluoroalkyl, and &#x2014;OR12; R9 is selected from H &#x2014;NR13C(O)R14 and &#x2014;C(O)NR10R11; R12 is selected from H, C-Calkyl and C-Ccycloalkyl, for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes. 

Pyridine derivatives as dipeptedyl peptidase inhibitors

The present invention is directed to compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein A is (II); X is selected from CH, CF and N, R8 is selected from H, C-Calkyl, aryl, heteroaryl, C-Calkylaryl, C-Calkylheteroaryl, C-Calkyl-O&#x2014;C-Calkyl, C-Chaloalkyl, hydroxy C-Calkyl, &#x2014;C(O)R9 and &#x2014;SOR9, or R7 and R8 combine to form (III), (IV); W is selected from CR1O and CR15, R1O is selected from H, halo, &#x2014;C(O)NR13R14, C-Calkyl, aryl, heteroaryl, C-Calkylaryl, C-Calkylheteroaryl, C-Calkyl-O&#x2014;C-Calkyl and hydroxy C-Calkyl; Het is a N-linked 5-membered heteroaryl ring optionally substituted with 1-3 substituents selected from methoxy, Cl, F, CH, CF, aryl, heteroaryl, C-Calkylaryl or C-Calkylheteroaryl, for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes. 

1-amino linked compounds

The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (xx); X is selected from CH, CF and N, R5 is selected from H, C-Calkyl, C-Cfluoroalkyl, and &#x2014;OR12, R9 is selected from H and &#x2014;C(O)NR1OR1 1, R12 is selected from H, C-Calkyl and C-Ccycloalkyl for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes. 

Phenyl compounds and their use in the treatment of Type II diabetes

The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction 

Melanocortin receptor agonists

The present invention relates to melanocortin receptor agonists of formula I, which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction 

Piperazine- and piperidine-derivatives as melanocortin receptor agonists

Disclosed are compounds which inhibit &#x3b2;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions that include a compound which inhibits &#x3b2;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &#x3b2;-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit &#x3b2;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &#x3b2;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions that include a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds

Growing community of inventors

Carmel, IN, United States of America

Qing Shi